Novartis job cuts affect hundreds in Swiss manufacturing, while Novo’s diabetes drug advances to Phase 3 trials.
Author: PharmaSignal News Desk
Otsuka FDA approval marks a first for anti-APRIL therapy targeting IgA nephropathy, impacting over 100,000 US patients.
Medicare price negotiation establishes 2027 prices for Wegovy and Trelegy, reducing spending by 44% over 2024 list prices.
Big Pharma CEO ratings reveal employee approval levels, highlighting leadership impact on companies.
Medicare Drug Prices for 15 drugs unveiled, saving $8.5 billion, a 36% reduction.
Kelun Merck ADC shows promise in lung cancer treatment, succeeding in a late-stage trial with potential for first-line approval.
Otsuka FDA approval marks a milestone with Voyxact for IgA nephropathy, a chronic kidney disease.
Novartis FDA Approval Itvisma expands treatment for spinal muscular atrophy to older patients, priced at $2.59 million.
Bayer Asundexian trial results indicate potential for a new cardiovascular drug class, raising hopes after previous clinical setbacks.
Novo Nordisk’s GLP-1 drug semaglutide fails to slow cognitive decline in Alzheimer’s trials.